Chinese traditional medicine preparations for treating eyeground hemorrhage vitreous opacity

Abstract

The present invention relates to a traditional Chinese medicine for treating eye diseases, in particular to a traditional Chinese medicine preparation for treating retinal hemorrhage and vitreous opacity. The present invention is composed of the pharmaceutical raw materials with the following parts by weight: danshen root 30, kudzuvine root 15, cassia seed 15, south dodder seed 15, cattail pollen 10, swordlike atractylodes rhizome 10, seaweed 10, kelp 10, baical skullcap root 6 and sanchi powder 2. Compared with the former obtained patent ZL03104746.7 by the applicant, the prescription composition of the present invention eliminates three traditional Chinese medicines of sea-ear shell, nacre and medicinal cyathula root, increases one medicine of kudzuvine root and adjusts the parts by weight of all the traditional Chinese medicines in the prescription composition. The modern pharmacological studies show that the puerarin contains flavonoids, which can improve the microcirculation, enhance the red cell deformability, reduce the aggregation, improves the blood flow, increase the local microcirculation blood flow and inhibit the platelet aggregation. Therefore, the prescription composition of the medicine is more scientific and reasonable; and the efficacy is more significant through the clinical observations in the past four years.

Description

Technical field: [0001] The invention relates to a traditional Chinese medicine for treating ophthalmic diseases, in particular to a traditional Chinese medicine preparation for treating fundus hemorrhage and vitreous opacity. Background technique: [0002] Vitreous hemorrhage is a common disease in ophthalmology, which seriously affects vision. Since the vitreous body itself has no blood vessels, its metabolism is slow, and it is difficult to absorb after hemorrhage, especially long-term repeated hemorrhage, can form proliferative vitreoretinopathy, and then lead to traction retinal detachment, so the clinical blindness rate is high. The patent ZL03104746.7 obtained by the applicant previously disclosed a traditional Chinese medicine preparation for treating vitreous opacity of fundus hemorrhage. After several years of clinical efficacy observation, the efficacy of the medicine in improving microcirculation and clearing accumulated blood needs to be further improved. Inve...

AI Technical Summary

Problems solved by technology

Because the vitreous body itself has no blood vessels, its metabolism is slow, and it is difficult to absorb after hemorrhage, especially long-term repeated hemorrhage, can form proliferative vitreoretinopathy, and then lead to traction retinal detachment, so the clinical blindness rate is high

The patent ZL03104746.7 obtained by the applicant earlier discloses a traditional Chinese medicine preparation for treating vitreous opacity of fundus hemorrhage. After several years of clinical efficacy observation, the efficacy of this medicine in improving microcirculation and clearing accumulated blood needs to be further improved